One of the most important targets in Alzheimer disease is Beta site amyloid precursor protein cleaving enzyme-1 (BACE-1). It is a membrane associated protein and is one of the main enzymes responsible for amyloid β (Aβ) production. Up to now, a considerable number of peptidic and non-peptidic inhibitors of BACE-1 have been developed. Recently, small molecule BACE-1 inhibitors have attracted the...

background and aims: diabetic nephropathy (dn) is the most common cause of end-stage renal failure which could increase the risk of cardiovascular disease and morbidity and mortality in patients. the aim of this study was to investigate new modalities for treatment of diabetic nephropathy. methods:this study was a mini-review research to investigate drugs that are used for dn treatment. results...

1. F. Cocchi et al., Science 270, 1811 (1995). 2. Y. Feng, C. C. Broder, P. E. Kennedy, E. A. Berger, ibid. 272, 872 (1996). 3. M. Samson, 0. Labbe, C. Mollereau, G. Vassart, M. Parmentier, Biochemistry 35, 3362 (1996); C. J. Raport, J. Gosling, V. L. Schweickart, P. W. Gray, I. F. Charo, J. Biol. Chem. 271, 17161 (1996). 4. H. Choe et al., Cell 85, 1135 (1996); B. J. Doranz et al., ibid., p. 1...

neuroleptic malignant syndrome (nms) is a rare fatal medical complication that occurs as a result of dopaminergic receptor blockage in the caudate at the termination of the nigrostriatal pathways (1), and may occur at any time following consumption of dopamine antagonists. this disorder also occurs in cases of sudden discontinuation of dopamine agonists and antagonists (2,3). some studies have ...

One of the most important targets in Alzheimer disease is Beta site amyloid precursor protein cleaving enzyme-1 (BACE-1). It is a membrane associated protein and is one of the main enzymes responsible for amyloid β (Aβ) production. Up to now, a considerable number of peptidic and non-peptidic inhibitors of BACE-1 have been developed. Recently, small molecule BACE-1 inhibitors have attracted the...

1. F. Cocchi et al., Science 270, 1811 (1995). 2. Y. Feng, C. C. Broder, P. E. Kennedy, E. A. Berger, ibid. 272, 872 (1996). 3. M. Samson, 0. Labbe, C. Mollereau, G. Vassart, M. Parmentier, Biochemistry 35, 3362 (1996); C. J. Raport, J. Gosling, V. L. Schweickart, P. W. Gray, I. F. Charo, J. Biol. Chem. 271, 17161 (1996). 4. H. Choe et al., Cell 85, 1135 (1996); B. J. Doranz et al., ibid., p. 1...

Glucagon-like peptide-1 (GLP-1) promotes insulin secretion, inhibits glucagon and repairs pancreatic islet cell function to enhance proliferation regeneration. Furthermore, it includes a mechanism for weight loss angiocarpy protection. This study covers the comparison of GLP-1 agonists with DPP-4 inhibitors GLT-2 inhibitors, agonists, its research possibilities based on summary current clinical...

The transient receptor potential melastatin 4 (TRPM4) ion channel is ubiquitously expressed. Dysregulation and/or functional mutations of TRPM4 lead to several diseases. Within our studies, we screened for inhibitors and identified small molecules that block in the low µM range. Furthermore, investigated pathophysiology cardiac conditions, immune diseases cancer using these novel inhibitors, mo...

Ovarian cancer (OC) is associated with a dismal prognosis and lack of curative treatment. Increased understanding OC biology has led to the development several targeted therapies, including antiangiogenic agents poly(ADP-ribose) polymerase (PARP) inhibitors. Cell cycle inhibitors endocrine therapy such as selective estrogen receptor down regulators are currently under development. In this artic...